Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$3.87M
Expense Ratio	0.59%
PE Ratio	26.66
Shares Out	180,000
Dividend (ttm)	$0.22
Dividend Yield	1.04%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	27.98%
1-Year Return	n/a

Volume	4,696
Open	21.19
Previous Close	21.16
Day's Range	21.15 - 21.19
52-Week Low	21.08
52-Week High	28.19
Beta	n/a
Holdings	28
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

69.85% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	15.61%
Novo Nordisk A/S	NVO	13.94%
Innovent Biologics, Inc.	1801	5.17%
Chugai Pharmaceutical Co., Ltd.	4519	5.12%
West Pharmaceutical Services, Inc.	WST	5.10%
Amgen Inc.	AMGN	5.08%
Roche Holding AG	ROG	5.01%
Pfizer Inc.	PFE	4.97%
Thermo Fisher Scientific Inc.	TMO	4.93%
AstraZeneca PLC	AZN	4.92%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024